Literature DB >> 20635511

Clinical isolates of Pantone-Valentine leucocidin- and gamma-haemolysin-producing Staphylococcus aureus: prevalence and association with clinical infections.

I Mesrati1, M Saïdani, S Ennigrou, B Zouari, S Ben Redjeb.   

Abstract

Pantone-Valentine leucocidin (PVL) and gAMMA-haemolysin (Hlg) are members of the synergohymenotropic toxin family produced by Staphylococcus aureus and encoded by pvl and hlg genes, respectively. Many reports describe an association between PVL toxin and necrotic lesions involving skin and mucosa. The aim of this study was to determine the prevalence of S. aureus strains carrying pvl and hlg genes and to investigate a possible relationship between pvl- and hlg-positive S. aureus with specific clinical presentations. Between January 2005 and July 2007, a total of 143 S. aureus strains including 58 meticillin-resistant S. aureus (MRSA) and 85 meticillin-susceptible S. aureus were screened for pvl and hlg genes by multiplex polymerase chain reaction. These strains were isolated from 141 patients for whom demographic and clinical data were recorded. Thirty-one (21.7%) and 77 (53.7%) isolates were positive for pvl and hlg genes, respectively. Twenty-one (67.7%) pvl-positive strains were MRSA (P = 0.001). Among pvl-positive strains, 16 (51.6%) were community-acquired. There was a strong association between pvl genes and skin and soft tissue infections, especially abscesses (60% of strains; P = 0.008) and furunculosis (55.5% of strains; P = 0.036). Our findings confirmed the association between pvl-positive strains, cutaneous infections and meticillin resistance in S. aureus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20635511     DOI: 10.1016/j.jhin.2010.03.015

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  8 in total

1.  Type I signal peptidase and protein secretion in Staphylococcus aureus.

Authors:  Mark A Schallenberger; Sherry Niessen; Changxia Shao; Bruce J Fowler; Floyd E Romesberg
Journal:  J Bacteriol       Date:  2012-03-23       Impact factor: 3.490

Review 2.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

3.  [Panton-Valentine leukocidin in patients with chronic wounds. Results from a clinical investigation in 100 patients].

Authors:  C Hammer; P-M Rath; J Steinmann; M Stoffels-Weindorf; J Klode; J Dissemond
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

4.  Epicutaneous model of community-acquired Staphylococcus aureus skin infections.

Authors:  Ranjani Prabhakara; Oded Foreman; Roberto De Pascalis; Gloria M Lee; Roger D Plaut; Stanley Y Kim; Scott Stibitz; Karen L Elkins; Tod J Merkel
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

Review 5.  Staphylococcus aureus Toxins: An Update on Their Pathogenic Properties and Potential Treatments.

Authors:  Nour Ahmad-Mansour; Paul Loubet; Cassandra Pouget; Catherine Dunyach-Remy; Albert Sotto; Jean-Philippe Lavigne; Virginie Molle
Journal:  Toxins (Basel)       Date:  2021-09-23       Impact factor: 4.546

Review 6.  The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis.

Authors:  Laura J Shallcross; Ellen Fragaszy; Anne M Johnson; Andrew C Hayward
Journal:  Lancet Infect Dis       Date:  2012-10-26       Impact factor: 25.071

7.  MRSA in Africa: filling the global map of antimicrobial resistance.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; John Leptidis; Ioanna P Korbila
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

8.  Detection of Alpha-Toxin and Other Virulence Factors in Biofilms of Staphylococcus aureus on Polystyrene and a Human Epidermal Model.

Authors:  P M den Reijer; E M Haisma; N A Lemmens-den Toom; J Willemse; R I Koning; R A Koning; J A A Demmers; D H W Dekkers; E Rijkers; A El Ghalbzouri; P H Nibbering; W van Wamel
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.